Affordable Access

Access to the full text

Update on quinolone-containing rescue therapies for Helicobacter pylori infection

Authors
  • Mori, Hideki
  • Suzuki, Hidekazu
Type
Published Article
Journal
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Inc
Publication Date
Apr 21, 2020
Volume
26
Issue
15
Pages
1733–1744
Identifiers
DOI: 10.3748/wjg.v26.i15.1733
PMID: 32351290
PMCID: PMC7183861
Source
PubMed Central
Keywords
License
Green

Abstract

Third generation of quinolones, such as levofloxacin and moxifloxacin, -containing regimens are often used in second-line or rescue treatment of Helicobacter pylori infection. However, the increasing antibiotic resistance to quinolones affects the efficacies of quinolones-containing therapies in recent years. Therefore, there is a need to enhance the effectiveness of quinolones-containing therapies. Sitafloxacin, a fourth-generation quinolone, and vonoprazan, a novel potassium-competitive acid blocker, are now available as more effective treatment options. The aim of this paper is to summarize the current evidence of quinolone-containing therapies in rescue treatments, and to discuss the importance of drug sensitivity tests or analysis of gyrA mutation before treatments.

Report this publication

Statistics

Seen <100 times